CA3030530C - Regimens and methods of treating multiple sclerosis using ofatumumab - Google Patents

Regimens and methods of treating multiple sclerosis using ofatumumab Download PDF

Info

Publication number
CA3030530C
CA3030530C CA3030530A CA3030530A CA3030530C CA 3030530 C CA3030530 C CA 3030530C CA 3030530 A CA3030530 A CA 3030530A CA 3030530 A CA3030530 A CA 3030530A CA 3030530 C CA3030530 C CA 3030530C
Authority
CA
Canada
Prior art keywords
ofatumumab
regimen
multiple sclerosis
antibody
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3030530A
Other languages
English (en)
French (fr)
Other versions
CA3030530A1 (en
Inventor
Erik Wallstrom
Marina SAVELIEVA PRAZ
Algirdas Jonas KAKARIEKA WEISSKOPF
Joseph Michael KAHN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CA3101514A priority Critical patent/CA3101514A1/en
Publication of CA3030530A1 publication Critical patent/CA3030530A1/en
Application granted granted Critical
Publication of CA3030530C publication Critical patent/CA3030530C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CA3030530A 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab Active CA3030530C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3101514A CA3101514A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
US62/374,986 2016-08-15
PCT/IB2017/054909 WO2018033841A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3101514A Division CA3101514A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Publications (2)

Publication Number Publication Date
CA3030530A1 CA3030530A1 (en) 2018-02-22
CA3030530C true CA3030530C (en) 2021-02-23

Family

ID=59901554

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3030530A Active CA3030530C (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab
CA3101514A Pending CA3101514A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3101514A Pending CA3101514A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Country Status (24)

Country Link
US (5) US11161909B2 (https=)
EP (5) EP3497132B1 (https=)
JP (2) JP6851391B2 (https=)
KR (2) KR20200136503A (https=)
CN (5) CN120000782A (https=)
AU (2) AU2017311664C1 (https=)
CA (2) CA3030530C (https=)
CY (1) CY1123350T1 (https=)
DE (1) DE202017007542U1 (https=)
DK (2) DK3733712T3 (https=)
ES (2) ES2954259T3 (https=)
FI (1) FI3733712T3 (https=)
HR (2) HRP20230894T1 (https=)
HU (2) HUE063625T2 (https=)
IL (4) IL302488B2 (https=)
LT (2) LT3733712T (https=)
MX (1) MX388593B (https=)
PL (2) PL3497132T3 (https=)
PT (2) PT3733712T (https=)
RS (2) RS60807B1 (https=)
RU (1) RU2749951C2 (https=)
SI (2) SI3497132T1 (https=)
TW (1) TWI752995B (https=)
WO (1) WO2018033841A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
EP4707302A2 (en) * 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20020064823A1 (en) 2000-03-30 2002-05-30 Welcher Andrew A. CD20/IgE-receptor like molecules and uses thereof
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2663331A4 (en) * 2011-01-10 2015-07-15 Glaxosmithkline Intellectual Property Man Ltd NEW USES
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
MX2022003010A (es) 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
EP4707302A2 (en) 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Also Published As

Publication number Publication date
JP6851391B2 (ja) 2021-03-31
IL302488B1 (en) 2024-08-01
KR20200136503A (ko) 2020-12-07
PT3497132T (pt) 2020-09-25
US12570754B2 (en) 2026-03-10
US20220081488A1 (en) 2022-03-17
RS60807B1 (sr) 2020-10-30
CN120053639A (zh) 2025-05-30
US20240150485A1 (en) 2024-05-09
MX388593B (es) 2025-03-20
US20240317878A1 (en) 2024-09-26
JP2020100630A (ja) 2020-07-02
IL264804B (en) 2020-09-30
CN120037367A (zh) 2025-05-27
MX2019001860A (es) 2019-07-08
AU2017311664A1 (en) 2019-01-31
IL276890A (en) 2020-10-29
PT3733712T (pt) 2023-08-31
AU2020201112B2 (en) 2021-07-22
EP4252847A3 (en) 2023-11-15
DK3733712T3 (da) 2023-08-21
DK3497132T3 (da) 2020-09-07
AU2017311664B2 (en) 2020-01-02
HUE051948T2 (hu) 2021-03-29
EP4711008A2 (en) 2026-03-18
AU2020201112C1 (en) 2025-05-22
HRP20201388T1 (hr) 2020-11-27
ES2954259T3 (es) 2023-11-21
EP3733712A1 (en) 2020-11-04
PL3497132T3 (pl) 2020-11-30
CN109641965A (zh) 2019-04-16
AU2020201112A1 (en) 2020-03-05
JP2019511506A (ja) 2019-04-25
HRP20230894T1 (hr) 2023-11-24
SI3497132T1 (sl) 2020-10-30
WO2018033841A1 (en) 2018-02-22
AU2017311664C1 (en) 2025-05-22
TWI752995B (zh) 2022-01-21
CA3101514A1 (en) 2018-02-22
IL276890B2 (en) 2023-10-01
IL302488A (en) 2023-06-01
EP4371611A2 (en) 2024-05-22
EP3733712B1 (en) 2023-05-24
IL302488B2 (en) 2024-12-01
CN120000782A (zh) 2025-05-16
ES2821924T3 (es) 2021-04-28
HUE063625T2 (hu) 2024-01-28
IL276890B1 (en) 2023-06-01
RS64541B1 (sr) 2023-09-29
CY1123350T1 (el) 2021-12-31
FI3733712T3 (fi) 2023-08-22
CN120053638A (zh) 2025-05-30
TW201808333A (zh) 2018-03-16
RU2019107146A (ru) 2020-09-15
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
PL3733712T3 (pl) 2023-10-16
RU2019107146A3 (https=) 2020-09-15
LT3733712T (lt) 2023-09-11
RU2021105514A (ru) 2021-04-19
DE202017007542U1 (de) 2022-07-19
US12338290B2 (en) 2025-06-24
SI3733712T1 (sl) 2023-12-29
EP4252847A2 (en) 2023-10-04
EP4371611A3 (en) 2024-07-24
IL313932A (en) 2024-08-01
US11161909B2 (en) 2021-11-02
JP7198786B2 (ja) 2023-01-04
EP3497132A1 (en) 2019-06-19
CA3030530A1 (en) 2018-02-22
EP3497132B1 (en) 2020-06-24
RU2749951C2 (ru) 2021-06-21
US20250289902A1 (en) 2025-09-18
RU2021105514A3 (https=) 2022-02-08
KR20190038914A (ko) 2019-04-09

Similar Documents

Publication Publication Date Title
US12570754B2 (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40101642A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40111448A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
RU2782069C2 (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
HK40032047A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40032047B (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40005527A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
HK40005527B (en) Regimens and methods of treating multiple sclerosis using ofatumumab

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20250829

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250829

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250909

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250909

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250909